Volume 133, Issue 3



January 17, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Risk of bleeding in cerebral cavernous malformations due to endothelial thrombomodulin and protein C receptors. See the article by Lopez-Ramirez et al.

Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice
This plenary paper links bleeding in cerebral cavernous malformations, which are common brain vascular defects, to anticoagulant activity of local endothelial cells, and it explores novel ways to reduce accompanying seizures and strokes.

Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis
The severity of cardiac involvement remains the primary prognostic factor in AL amyloidosis. In this study, the authors sought to update the Mayo cardiac staging system by examining a contemporary cohort of patients treated with modern frontline therapy and exploring the utility of replacing the established N-terminal pro–brain natriuretic peptide (NT-proBNP) with the more widely available BNP.

Dual cholinergic signals regulate daily migration of hematopoietic stem cells and leukocytes
The data in this paper reveal critical roles of cholinergic pathways in circadian regulation of hematopoietic stem cell–trafficking dynamics.

Resolution of sickle cell disease–associated inflammation and tissue damage with 17R-resolvin D1
This study demonstrates that sickle cell disease (SCD) disrupts an entirely new pathogenetic pathway that may be targeted to treat the disease. These data provide compelling evidence that there is a defect in the inflammation-resolution response in the humanized model for SCD and that its restoration with the addition of 17R-resolvin D1 prevents tissue injury.

The transmembrane protein disulfide isomerase TMX1 negatively regulates platelet responses
The authors report thioredoxin-related transmembrane protein 1 (TMX1) as the first antithrombotic vascular thiol isomerase. The intrinsic platelet membrane oxidoreductase TMX1, the fifth member of the protein disulfide isomerase family of enzymes, is required for normal platelet function and thrombosis in mice.

How I treat infant leukemia
This How I Treat article presents a comprehensive overview of the current status of the presentation of infant leukemia and a discussion of the new therapeutic agents for the disease.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.